<DOC>
	<DOCNO>NCT02167035</DOCNO>
	<brief_summary>To compare Combigan BID vs Simbrinza TID subject currently treat Latanoprost Open-Angle Glaucoma Ocular Hypertension . Both drug currently FDA approve combination therapy patient Open-Angle Glaucoma Ocular Hypertension . The purpose clinical trial would assess treatment , either , superior lower intraocular pressure ( IOP ) . A secondary objective ass tolerability drug .</brief_summary>
	<brief_title>Comparison Combigan BID Versus Simbrinza TID</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Brimonidine Tartrate , Timolol Maleate Drug Combination</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>Openangle glaucoma ocular Hypertension Currently treat Latanoprost min 6 week Male Female 18 yr old Best Corrected Visual Acuity 20/100 good eye Pachymetry &gt; 470 &lt; 640 Women childbearing potential must negative urine pregnancy test screening/baseline visit Patient willing capable providing inform consent C/D &gt; 0.8 Visual field loss , opinion investigator functionally significant Current use ocular steroid Concurrent significant active ocular disease History ( within 3 month prior Screening ) ocular laser , intraocular , filter refractive surgery plan ocular surgery kind study participation Change within prior 30 day anticipate change systemic medication know affect IOP Uncontrolled systemic disease Significant ocular hyperemia baseline Prior glaucoma procedure within 3 month Females pregnant , nursing , plan pregnancy childbearing potential use reliable method contraception Known allergy sensitivity study medication Asthma known medical condition investigator feel would put patient increase risk study medication Current enrollment investigational drug device study participation study within 30 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>